First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
NCT ID: NCT01529307
Last Updated: 2020-12-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
6 participants
INTERVENTIONAL
2012-06-30
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TAS266
TAS266
TAS266 IV infusions given weekly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TAS266
TAS266 IV infusions given weekly
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years or older
* ECOG performance status of 0, 1 or 2
* Adequate bone marrow, hepatic and renal function
* Obtained written informed consent
Exclusion Criteria
* Major surgery within 4 weeks before study treatment
* Prior anaphylactic or other severe infusion reactions to human immunoglobulin or antibody formulations
* Impaired cardiac functions
* Previous hepatitis viral infection such as hepatitis B or hepatitis C
* Diagnosis of HIV infection
* Pregnant or nursing (lactating) women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
H. Lee Moffitt Cancer Center/University of South Florida Moffitt SC
Tampa, Florida, United States
South Texas Accelerated Research Therapeutics START
San Antonio, Texas, United States
University of Utah / Huntsman Cancer Institute Huntsman UT
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CTAS266X2101 can be found on the Novartis Clinical Trial Results Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTAS266X2101
Identifier Type: -
Identifier Source: org_study_id